ClinicalTrials.gg
TerminatedNCT02091752Updated Mar 24, 2016Results posted

A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)

A Phase 2 interventional study of Ruxolitinib in Primary Myelofibrosis, sponsored by Novartis Pharmaceuticals. Terminated at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-24.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated due to low enrollment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 50 studies testing ruxolitinib in Primary Myelofibrosis — 8 open to participants now, 15 under way, 1 of them phase 3. ruxolitinib · Primary Myelofibrosis.

Enrollment
47th of 50
3 · median 45
Started
2014
with 2 others
Phase 2
19 of 50
3 open now
Registered
19th of 50
by date
Lead sponsor
11 of 50
Novartis Pharmaceuticals

Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, this one is the 47th largest by enrollment, is one of 3 that started in 2014, is one of 19 in phase 2, and was the 19th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

8 of the 50 studies testing ruxolitinib in Primary Myelofibrosis are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 101 Primary Myelofibrosis studies recruiting now, 83 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing ruxolitinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

The aim of the study is to assess the efficacy and safety of restarting ruxolitinib after treatment interruption due to loss of response and/or adverse events.

03

Conditions studied

  • Primary Myelofibrosis

Keywords

  • Primary Myelofibrosis
  • Hematologic Diseases
  • Myeloproliferative Disorders
  • INC424
  • Ruxolitinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of PMF, PPV MF or PET-MF, irrespective of JAK2 mutational status according to the 2008 revised International Standard Criteria
  • Peripheral blast count \< 10%
  • Requires therapy for MF in the opinion of the investigator
  • Received prior monotherapy treatment with ruxolitinib for at least 12 consecutive weeks and experienced treatment interruption because of lossof response or adverse event
  • Patients adhering to the Screening phase assessments and undergoing a a ruxolitinib-free of a minimum of 1 week and a maximum of 8 weeks
  • performance status 0, 1, 2, or 3
  • Adequate bone marrow function
  • Written

Exclusion criteria

Exclusion Criteria:

  • Patients not initially responding (primary resistance) to ruxolitinib therapy
  • Patients who underwent a splenectomy or spleen radiation
  • Patients currently scheduled for bone marrow transplant
  • Patients who have discontinued ruxolitinib \< 14 days prior to screening
  • Patients who are not able to receive a starting dose of ruxolitinib of at least 15 mg total daily dose
  • Leukemic transformation
  • Inadequate renal function
  • Presence of active bacterial, fungal, parasitic or viral infection which requires therapy
  • Previous history of Progressive Multifocal Leuko-encephalopathy (PML)
  • Clinically significant cardiac disease or significant concurrent medical condition
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Ruxolitinib

    All participants received ruxolitinib.

    Drug: Ruxolitinib

Interventions

  • Starting dose was based on reason for previous discontinuation of ruxolitinib (i.e. loss of response or AE) and baseline platelet count. For participants who previously discontinued ruxolitinib due to loss of response, the starting dose was determined based on baseline platelet counts as follows: participants with a baseline platelet count of ≥ 200 x 109/L began dosing at 20 mg po bid; participants with a baseline platelet count of 100 x 109/L to \<200 x 109/L began dosing at 15 mg po bid. Participants who previously discontinued ruxolitinib due to an AE initiated therapy at a total daily dose 5 mg lower than the total daily dose prior to discontinuation.

06

What researchers measure

Primary outcomes

  1. Proportion of Patients Achieving ≥20% Reduction From Baseline in Spleen Volume

    Time frame: Week 24

Secondary outcomes

  1. Proportion of Patients Achieving ≥35% Reduction From Baseline in Spleen Volume

    Time frame: Week 24

  2. Proportion of Patients Achieving ≥25% and ≥50% Reduction, Respectively From Baseline, in Spleen Length

    Time frame: Week 24

  3. Change From Baseline in Spleen Length and Spleen Volume

    Time frame: Baseline, Week 24

  4. Proportion of Patients Achieving ≥25% and ≥50% Reduction, Respectively, From Baseline in Total Symptom Score (MPN-SAF TSS)

    Time frame: Week 24

  5. Change From Baseline in MPN-SAF TSS Score

    Time frame: Baseline, Week 24

  6. Patient Global Impression of Change (PGIC) Score

    Time frame: Week 1, Week 24

  7. Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and EuroQol (EQ)-5D-5L Scores

    Time frame: Baseline, Day 1, Week 8, Week 12, Week 16, Week 24

07

Results

Posted Feb 10, 2016

Participant flow

Participant flow — Overall Study
MilestoneRuxolitinib
Started3
Completed0
Not completed3
Withdrew: Study terminated by sponsor2
Withdrew: Adverse event1

Outcome measures

PrimaryProportion of Patients Achieving ≥20% Reduction From Baseline in Spleen Volume
Time frame:
Week 24

No measurements were reported for this outcome.

SecondaryProportion of Patients Achieving ≥35% Reduction From Baseline in Spleen Volume
Time frame:
Week 24

No measurements were reported for this outcome.

SecondaryProportion of Patients Achieving ≥25% and ≥50% Reduction, Respectively From Baseline, in Spleen Length
Time frame:
Week 24

No measurements were reported for this outcome.

SecondaryChange From Baseline in Spleen Length and Spleen Volume
Time frame:
Baseline, Week 24

No measurements were reported for this outcome.

SecondaryProportion of Patients Achieving ≥25% and ≥50% Reduction, Respectively, From Baseline in Total Symptom Score (MPN-SAF TSS)
Time frame:
Week 24

No measurements were reported for this outcome.

SecondaryChange From Baseline in MPN-SAF TSS Score
Time frame:
Baseline, Week 24

No measurements were reported for this outcome.

SecondaryPatient Global Impression of Change (PGIC) Score
Time frame:
Week 1, Week 24

No measurements were reported for this outcome.

SecondaryChange From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and EuroQol (EQ)-5D-5L Scores
Time frame:
Baseline, Day 1, Week 8, Week 12, Week 16, Week 24

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ruxolitinib—2/3 (66.7%)2/3 (66.7%)
Most frequent serious events
Most frequent serious events
EventRuxolitinib
CONSTIPATIONGastrointestinal disorders1/3
CYTOKINE RELEASE SYNDROMEImmune system disorders1/3
LISTERIOSISInfections and infestations1/3
RENAL FAILURERenal and urinary disorders1/3
Most frequent other events
Most frequent other events
EventRuxolitinib
ANAEMIABlood and lymphatic system disorders1/3
ANAL HAEMORRHAGEGastrointestinal disorders1/3
ASCITESGastrointestinal disorders1/3
CONSTIPATIONGastrointestinal disorders1/3
DIARRHOEAGastrointestinal disorders1/3
VARICES OESOPHAGEALGastrointestinal disorders1/3
PORTAL VEIN THROMBOSISHepatobiliary disorders1/3
CYSTITISInfections and infestations1/3
ALANINE AMINOTRANSFERASE INCREASEDInvestigations1/3
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations1/3

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Ruxolitinib
Mean68.00 ± 9.165
Sex: Female, Male
Sex: Female, Male(Participants)Ruxolitinib
Female2
Male1
08

Study locations

3 sites
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Firenze, FI 50134, Italy
  • Novartis Investigative Site
    Madrid, 28034, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2014
First posted
Mar 19, 2014
Start
Sep 2014
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Results first posted
Feb 10, 2016
Last update
Mar 24, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02091752
Responsible party
Sponsor
First posted
Mar 19, 2014
Start date
Sep 2014
Primary completion
Feb 2015
Completion
Feb 2015
Results posted
Feb 10, 2016
Last update
Mar 24, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion